Intas Pharmaceuticals has entered into an exclusive agreement with IntegriMedical for the introduction of a needle-free injection system for use in IVF and gynaecology treatments in India. IntegriMedical is the developer of India’s needle-free injection system.
Under the agreement, Intas will introduce the needle-free injection system for IVF and gynaecology therapies in India. The agreement provides Intas with exclusivity for the use of the system in these therapy areas.
Through this collaboration, Intas will offer IVF and gynaecology therapies using needle-free injections in India. The agreement focuses on changes in the delivery of treatment and patient experience in reproductive care.
The collaboration will use IntegriMedical’s drug delivery technology to address injection-related discomfort and anxiety and to support treatment compliance and patient satisfaction. As part of the agreement, Intas and IntegriMedical will work together to deploy the needle-free injection system across IVF clinics and gynaecology centres in India.
India records an estimated 300,000 to 350,000 IVF cycles each year. Projections indicate this could increase to 500,000 to 600,000 cycles by 2027. This results in several million injections administered each year as part of IVF treatment in India. The integration of needle-free injection technology into IVF treatment is expected to impact the treatment experience for women undergoing these procedures.
Commenting on the collaboration, Sarvesh Mutha, Managing Director, IntegriMedical, said, “It’s incredibly rewarding to see our vision come to life through this groundbreaking collaboration with Intas. For IntegriMedical, this is more than a technical achievement, it’s about making treatments less intimidating, more comfortable, and truly humane. Congratulations to the Intas team for leading this country-first initiative in IVF and gynecology. Together, we are taking a meaningful step forward in putting patients at the heart of care.”
Durga P Satapathy, Executive Vice President, Intas, said, “This initiative is about more than introducing a new technology; it’s about changing how patients experience care. IVF and gynecology treatments can be demanding, and our goal is to make every step easier, more reassuring, and more dignified. Collaborations like this show what’s possible when innovation is truly focused on people. By leading such patient-centric advancements, we are setting a new benchmark for care in the country.”
The needle-free injection system delivers medication through a high-pressure jet stream mechanism in a spray-like pattern. The medication is administered through a micro-orifice in the skin without the use of needles. The system reduces tissue impact, avoids medication pooling, and lowers the risk of cross-contamination.
The agreement brings together Intas Pharmaceuticals and IntegriMedical to introduce needle-free injection technology for IVF and gynaecology treatment in India.